Company: LNAI
Filing Date: 2025-09-29
Form Type: 10-K
Source: 0001731122-25-001316
Chunk: 35

Company: Lunai Bioworks Inc.
Filing Date: 2025-09-29
Form: 10-K
Item: Item 1A
Chunk 35
---
 Cube’s or BioSymetrics’ business, results of operations and financial condition.

Renovaro Cube and BioSymetrics
may also be subject to liability claims for damages related to real or perceived errors, failures, bugs, or defects in its platform or
future products. A material liability claim or other occurrence that harms Renovaro Cube’s or BioSymetrics’ reputation or
decreases market acceptance of its platform or future products may harm its business and results of operations. Finally, since some of
Renovaro Cube’s or BioSymetrics’ customers use its products for compliance reasons, any errors, failures, bugs, defects, disruptions
in service or other performance problems with Renovaro Cube’s or BioSymetrics’ products may damage its customers’ businesses
and could hurt its reputation.

Renovaro
Cube’s or BioSymetrics’ internal computer systems, or those expected to be used by its third-party research institution collaborators
or other contractors or consultants, may fail or suffer security breaches.

Despite
the implementation of security and back-up measures, Renovaro Cube’s or BioSymetrics’ internal computer, server
and other information technology systems as well as those of its third-party collaborators, consultants, contractors, suppliers
and service providers, may be vulnerable to damage from physical or electronic break-ins, computer viruses, malware, ransomware,
denial of service and other cyber-attacks or disruptive incidents that could result in unauthorized access to, use or disclosure
of, corruption of, or loss of sensitive and/or proprietary data, including personal and health information, and could subject Renovaro
Cube or BioSymetrics to significant liabilities, regulatory and enforcement actions and reputational damage. For example, the loss of
clinical study data from future clinical studies could result in delays in any regulatory clearance or approval efforts and significantly
increase Renovaro Cube’s or BioSymetrics’ costs to recover or reproduce the data, and subsequently commercialize its future
products. If Renovaro Cube, BioSymetrics’ or either’s third-party collaborators, consultants, contractors, suppliers
or service providers were to suffer an attack or breach, for example, that resulted in the unauthorized access to or use or disclosure
of personal or health information, Renovaro Cube or BioSymetrics may have to notify physicians, patients, partners,

38

collaborators, government
authorities and the media, and may be subject to investigations, civil